Publications

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase Ii Nrg-Gy023 Trial

AuthID
P-018-PDC

Author(s)

Lee, J

Miller, A

Rose, PG

AlHilli, M

Washington, C

John, VS

Shah, CA

Matsuo, K

Siedel, J

Miller, DS

Hopp, EE

O’Shea, A

Chan, JK

Bradford, LS

Morse, CB

Nagel, CI

Rodabaugh, KJ

Kohn, EC

Moore, KN

Liu, JF

Document Type

Article

Year published

2025

Published

in Clinical Cancer Research, ISSN: 1078-0432

Pages: OF1-OF9

Indexing

Crossref^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1158/1078-0432.ccr-24-3877

Source Identifiers

ISSN: 1078-0432

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase Ii Nrg-Gy023 Trial

Useful Links

Get Help

Federated Authentication (Click on the image)

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase Ii Nrg-Gy023 Trial

Useful Links

Get Help